completed2024-09-01D series

Insulin icodec

Diabetes mellitus Typ 1

Open official case page ↗

Brand: Awiqli
Manufacturer: Novo Nordisk Pharma GmbH

G-BA action

final resolution

2025-04-23

Arzneimittel-Richtlinie/Anlage XII: Insulin icodec (Diabetes mellitus Typ 1) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2025-04-23. The official page states that it took effect as follows: 25.04.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 7071 →

Patient group

Erwachsene mit Diabetes mellitus Typ 1

Added benefit not proven

Comparator
– Humaninsulin oder Insulinanaloga (Insulin detemir, Insulin glargin, Insulin degludec, Insulin aspart, Insulin glulisin, Insulin lispro)

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2025-01-06

80 parsed turns

Oral hearing: Insulin icodec (Diabetes mellitus Typ 1)

Official Wortprotokoll · 12 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A24-90

matched

Insulin icodec (type 1 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

Official assessment PDF · 83 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

2 decision

2025-02-20

final resolution

Arzneimittel-Richtlinie/Anlage XII: Insulin icodec (Diabetes mellitus Typ 1)

The G-BA found no proven added benefit for Erwachsene mit Diabetes mellitus Typ 1. The appropriate comparator was – Humaninsulin oder Insulinanaloga (Insulin detemir, Insulin glargin, Insulin degludec, Insulin aspart, Insulin glulisin, Insulin lispro). The G-BA issued a final resolution on 2025-02-20. The official page states that it took effect as follows: 20.02.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

3 official documents · 4 cited claims

Open decision →

2025-04-23

final resolution